The UK Government’s recently released “Levelling up White Paper” makes for interesting reading in the context of the life sciences sector.
In advance of a more in-depth review, here are some of the key points and my thoughts, focusing on two of the main areas of relevance to the sector: small company finance and R&D expenditure.